Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$162.68 USD

162.68
195,006

+0.27 (0.17%)

Updated Nov 11, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What Makes Masimo (MASI) a New Buy Stock

by Zacks Equity Research

Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Masimo (MASI) Q2 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Strength in Healthcare revenues drive Masimo's (MASI) second-quarter results.

Compared to Estimates, Masimo (MASI) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Masimo (MASI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 0% and 8.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.

Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.68% and 0.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet

by Zacks Equity Research

Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.

Masimo (MASI) Gets Non-Binding Offer for Consumer Business

by Zacks Equity Research

Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

by Zacks Equity Research

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

Masimo (MASI) Fights Politan in a Bid to Retain CEO on Board

by Zacks Equity Research

Will Masimo (MASI) lose its CEO in its fight against activist investor Politan Capital Management? The company's management and employees want Joe Kiani to continue as the CEO.

Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature

by Zacks Equity Research

Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.

Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care

by Zacks Equity Research

Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.

Urmimala Biswas headshot

3 Medical Instruments Picks to Navigate Industry Challenges

by Urmimala Biswas

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

Sanghamitra Saha headshot

5 Sector ETFs & Stocks to Benefit From May Inflation Report

by Sanghamitra Saha

US annual inflation rate slowed to 3.3% in May 2024, the lowest in three months, compared to 3.4% in April and forecasts of 3.4%.

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

Best Momentum Stocks to Buy for June 5th

by Zacks Equity Research

BAC, GPS and MASI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2024.

Nalak Das headshot

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Masimo's (MASI) New Offering to Serve Personalized Audio Market

by Zacks Equity Research

Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

by Zacks Equity Research

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Masimo (MASI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of 4.56% and 1.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.